BGC-515 is under clinical development by BridGene Biosciences and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BGC-515’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BGC-515 overview
BGC-515 is under development for the treatment of advanced solid tumors which include metastatic mesothelioma (MM) and epithelioid hemangioendothelioma (EHE). The drug candidate is administered through oral route and it acts by targeting transcriptional enhanced associate domain (TEAD). It is being developed based on Chemoproteomics platform, IMTAC (Isobaric Mass Tagged Affinity Characterization).
BridGene Biosciences overview
BridGene Biosciences, a biotechnology company using cutting-edge technology to discover and develop small molecules for hard-to-drug therapeutic targets. The company is headquartered United States.
For a complete picture of BGC-515’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
